Table 1.
Correlation between RIZ1 immunoreactivity and clinicopathologic features
| RIZ1 immunoreactivity (Median = 8.0) | ||||
|---|---|---|---|---|
| Features | N(N = 51, %) | <Median | ≥Median | P-values |
| Gender | 0.097 | |||
| Male | 32(62.7) | 19 | 13 | |
| Female | 19(37.3) | 6 | 13 | |
| Age | 0.027* | |||
| < 50 years | 29(56.9) | 12 | 17 | |
| ≥ 50 years | 22(43.1) | 13 | 9 | |
| Tumor diameter | 0.324 | |||
| < 6 cm | 32(62.7) | 14 | 18 | |
| ≥ 6 cm | 19(37.3) | 11 | 8 | |
| Extent of resection | 0.436 | |||
| Gross-total | 39(76.5) | 20 | 19 | |
| Sub-total | 12(23.5) | 5 | 7 | |
| Pathological grade | 0.000* | |||
| Low grade | 12(23.5) | 1 | 11 | |
| High grade | 39(76.5) | 24 | 15 | |
| Ki-67 immunoreactivity | ||||
| < Median | 24(47.1) | |||
| ≥ Median | 27(52.9) | |||
* P < 0.05 was considered statistically significant
Table 1: Clinicopathological evaluation suggested that RIZ1 expression was associated with tumor grade (p = 0.000) and patient age (P = 0.027)